Lupus

Addition of the recombinant fusion protein telitacicept to standard care may reduce disease activity and is well tolerated in people with systemic lupus erythematosus, research suggests.

Dapagliflozin deserves further study as an add-on therapy for reducing renal and cardiovascular risk in patients with systemic lupus erythematosus, suggest preliminary trial findings.

A large study published in The Lancet has found that people with autoimmune diseases have an approximately 1.4–3.6-fold increased risk for developing cardiovascular disease relative to the general population.

An exploratory analysis of data from the phase 2b BEAT LUPUS trial suggests that IgA2 anti-dsDNA antibody levels may be able to predict response to B cell-targeted therapies in patients with systemic lupus erythematosus.

Addition of the recombinant fusion protein telitacicept to standard care may reduce disease activity and is well tolerated in people with systemic lupus erythematosus, research suggests.

Achievement of LLDAS is associated with a significant reduction in mortality risk among people with systemic lupus erythematosus, study findings suggest.